• Collaboration to Increase COVID-19 Antigen Production
    Dr Ryan Cawood
  • Dr Andrew Lane

News

Collaboration to Increase COVID-19 Antigen Production

A partnership that will combine OXGENE’s proprietary Adenoviral Protein Machine Technology with The Native Antigen Company’s antigen development expertise is set to scale antigen manufacturing capabilities to deliver high-purity, recombinant proteins for the development of diagnostics and vaccines.

OXGENE’s technology based on production of viral proteins in mammalian cells using an adenoviral expression vector, is genetically modified into making SARS-CoV-2 proteins rather than its own, thereby harnessing the innate power of highly scalable viral protein production. The Native Antigen Company’s recombinant SARS-CoV-2 antigens are produced in mammalian cells to ensure full glycosylation and proper protein folding, both of which are essential for full biological and antigenic activity

Unlike the PCR tests that are currently being used, these diagnostics will be able to confirm past infections and determine levels of immunity to SARS-CoV-2, which could be invaluable for disease modelling and public health policy. Dr Ryan Cawood, Chief Executive, OXGENE, said: “Our novel Protein Machine Technology represents a significant development in the rapid and scalable generation of high-quality viral proteins. We’re delighted that by collaborating with The Native Antigen Company, we can take advantage of our technology to support the needs of researchers racing to develop much-needed diagnostics and vaccines against COVID-19.”

Dr Andy Lane, Commercial Director, The Native Antigen Company, said: “We are committed to developing the highest-quality reagents in rapid response to emerging epidemic diseases. Since the start of the crisis, the demand for our COVID-19 antigens has increased significantly, and by scaling up production of these vital reagents in collaboration with OXGENE, we hope to be able to support more researchers in their critical work developing diagnostics and vaccines.”

OXGENE and The Native Antigen Company aim to complete the first validation of this new paradigm in protein expression within the next month, which could have a demonstrable impact on the race to develop diagnostic kits and vaccines against this virus.


Digital Edition

ILM Guide 2025/26

June 2025

Buyers' Guide Listings- Product Listings by Category- Suppliers Listings (A-Z)Chromatography Articles- Setting the power coefficient and the baseline to linearise the signal of the evaporative ligh...

View all digital editions

Events

AUTOMATICON

Jun 24 2025 Warsaw, Poland

CPhI & P-MEC China 2025

Jun 24 2025 Shanghai, China

Discovery & Development Europe 2025

Jul 01 2025 Basel, Switzerland

MMC 2025

Jul 01 2025 Manchester, UK

analytica Lab Africa

Jul 08 2025 Johannesburg, South Africa

View all events